Lupron: Global Drug Analysis and Forecasts to 2026 – ResearchAndMarkets.com

DUBLIN–()–The “Drug
Analysis: Lupron”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Lupron (leuprolide; Takeda/AbbVie) is a gonadotropin-releasing hormone
(GnRH) agonist which acts on the pituitary gland in the brain to
stimulate luteinizing hormone (LH) release, resulting in a temporary
surge in serum testosterone levels known as “flare”.

With continued use, GnRH agonists such as Lupron cause downregulation of
GnRH receptors in the pituitary gland, generating a significant
reduction in LH and follicle-stimulating hormone secretion. This has the
effect of complete shutdown of testosterone production in the testes,
resulting in chemical castration where levels of the hormone drop by up
to 95% and tumor growth is significantly reduced.

Key Topics Covered:

Product Profiles

Lupron: Prostate cancer

List of Figures

Figure 1: Lupron sales for prostate cancer across the US, Japan, and
five major EU markets, by country, 2017-26

List of Tables

Table 1: Lupron sales for prostate cancer across the US, Japan, and five
major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7fzxfb/lupron_global?w=4



Source link

more recommended stories

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: